In a mixed interim data drop, Arcturus Therapeutics has revealed a lack of efficacy for its investigational inhaled mRNA therapy in cystic fibrosis (CF). The findings, shared today before market open, ...
Arcturus Therapeutics (NASDAQ:ARCT) traded lower on Friday after Citi downgraded the San Diego, California-based biotech, citing mid-stage data the company posted this week for ARCT-032, a messenger ...
Arcturus Therapeutics (ARCT) shares soared 8.7% in the last trading session to close at $19.62. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback